open access

Vol 61, No 5 (2010)
Case report
Published online: 2010-11-04
Submitted: 2013-02-15
Get Citation

The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated

Iwona Pałyga, Aldona Kowalska, Danuta Gąsior-Perczak, Małgorzata Tarnawska-Pierścińska, Janusz Słuszniak, Jacek Sygut, Stanisław Góźdź
Endokrynologia Polska 2010;61(5):507-511.

open access

Vol 61, No 5 (2010)
Case report
Published online: 2010-11-04
Submitted: 2013-02-15

Abstract


Introduction: Calcitonin is a very sensitive marker of medullary thyroid carcinoma (MTC). High concentrations of basal or pentagastrin stimulated calcitonin in patients with MTC is a signal of recurrence or metastatic disease. Detection of metastatic foci remains a diagnostic and therapeutic challenge.
The aim of the study was to present examples of the use of 68Ga-DOTA-TATE PET-CT examinations in the diagnosis of patients with MTC and concomitant elevated serum calcitonin concentrations.
Initially the study involved eight patients with MTC and elevated basal or stimulated calcitonin, in which earlier diagnostic imaging was negative for metastasis: neck ultrasound, chest and mediastinal CT scan, liver MRI, bone scintigraphy, and 18F-FDG-PET. A total body scan was performed using 68Ga-DOTA-TATE PET-CT. Two patients with positive diagnostic imaging tests were referred for surgery including resection of cervical lymph nodes with histopathological examination for assessment of metastases.
Conclusions: On the basis of the presented cases we conclude that PET-CT scan with somatostatin analogue labelled with gallium (68Ga-DOTA-TATE PET-CT) may be useful in the diagnostic imaging of patients with disseminated MTC.
(Pol J Endocrinol 2010; 61 (5): 507-511)

Abstract


Introduction: Calcitonin is a very sensitive marker of medullary thyroid carcinoma (MTC). High concentrations of basal or pentagastrin stimulated calcitonin in patients with MTC is a signal of recurrence or metastatic disease. Detection of metastatic foci remains a diagnostic and therapeutic challenge.
The aim of the study was to present examples of the use of 68Ga-DOTA-TATE PET-CT examinations in the diagnosis of patients with MTC and concomitant elevated serum calcitonin concentrations.
Initially the study involved eight patients with MTC and elevated basal or stimulated calcitonin, in which earlier diagnostic imaging was negative for metastasis: neck ultrasound, chest and mediastinal CT scan, liver MRI, bone scintigraphy, and 18F-FDG-PET. A total body scan was performed using 68Ga-DOTA-TATE PET-CT. Two patients with positive diagnostic imaging tests were referred for surgery including resection of cervical lymph nodes with histopathological examination for assessment of metastases.
Conclusions: On the basis of the presented cases we conclude that PET-CT scan with somatostatin analogue labelled with gallium (68Ga-DOTA-TATE PET-CT) may be useful in the diagnostic imaging of patients with disseminated MTC.
(Pol J Endocrinol 2010; 61 (5): 507-511)
Get Citation

Keywords

medullary thyroid carcinoma; 68Ga-DOTA-TATE; positron-emission tomography; calcitonin; neoplasm metastasis

About this article
Title

The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated

Journal

Endokrynologia Polska

Issue

Vol 61, No 5 (2010)

Pages

507-511

Published online

2010-11-04

Bibliographic record

Endokrynologia Polska 2010;61(5):507-511.

Keywords

medullary thyroid carcinoma
68Ga-DOTA-TATE
positron-emission tomography
calcitonin
neoplasm metastasis

Authors

Iwona Pałyga
Aldona Kowalska
Danuta Gąsior-Perczak
Małgorzata Tarnawska-Pierścińska
Janusz Słuszniak
Jacek Sygut
Stanisław Góźdź

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl